Phaseline

Companies › Guangzhou JOYO Pharma

Guangzhou JOYO Pharma: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 1; Oncology, Respiratory, Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JYP0015
Pan-RAS inhibitor targeting the active (ON) form of wild-type and mutant RAS
KRAS, NRAS, HRASPhase 2Solid TumorDec 2026
SC1011
antifibrotic agent
–Phase 2Idiopathic Pulmonary FibrosisDec 2026
JYP0061–Phase 2Neuromyelitis Optica Spectrum Disorders–
JYP0322
ROS1 tyrosine kinase inhibitor
ROS1Phase 1Protein Kinase InhibitorsDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06697535JYP0061Phase 2Neuromyelitis Optica Spectrum DisordersNeurologyFeb 2026
NCT06125327SC1011Phase 2Idiopathic Pulmonary FibrosisRespiratoryDec 2026
NCT06895031JYP0015Phase 2Solid TumorOncologyDec 2026
NCT06128148JYP0322Phase 1Protein Kinase InhibitorsOncologyDec 2027

Targets

KRAS (1) NRAS (1) HRAS (1) ROS1 (1)

Companies with the same targets

Revolution Medicines Adlai Nortye Biopharma TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Roche Bristol-Myers Squibb Quanta Therapeutics Eli Lilly Shanghai YingLi Pharmaceutical Amgen Novartis

Companies built like this

Blueprint Medicines Avistone Biotechnology Ranok Therapeutics (Hangzhou) Genfleet Therapeutics (Shanghai) TaiRx

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.